Blog
Exploring the Synthesis of Janssen's RSV-F Inhibitor Using ChemAIRS_EP03
ChemAIRS, our AI-driven retrosynthesis platform, predicted Janssen’s synthetic route for a potent RSV fusion inhibitor—targeting a virus that hospitalizes vulnerable populations—and proposed a cost-effective alternative. This demonstrates ChemAIRS’ ability to generate optimized, customizable pathways for efficient drug synthesis.
Utilizing ChemAIRS to investigate synthesis strategy of PRMT5 inhibitor from Gilead Sciences_EP01
ChemAIRS delivers AI-powered retrosynthesis for PRMT5 inhibitors—key epigenetic cancer targets—generating efficient, novel routes aligned with Gilead Sciences' research. Accelerate your drug discovery with reliable, unreported synthetic strategies for next-generation therapies
Optimizing Synthetic Strategies of Genentech's EPB inhibitor with ChemAIRS_EP02
"ChemAIRS rapidly generated unreported synthetic routes for Genentech & Convelo’s brain-penetrant EBP inhibitor—a breakthrough remyelination therapy—delivering cost-efficient pathways in minutes. Transform your CNS drug discovery with AI-driven retrosynthesis.
Using ChemAIRS to Accelerate Discovery of Synthetic Strategies for KT474: A Selective, Orally Bioavailable Heterobifunctional IRAK4 Degrader from Kymera Therapeutics_EP14
ChemAIRS optimized Kymera/Sanofi’s Phase 2 IRAK4 degrader KT-474—proposing scalable synthetic strategies that enhance efficiency, prevent side reactions, and streamline scale-up. Transform your targeted protein degrader development with AI-driven retrosynthesis
Enhancing Synthetic Pathways and Tackling Impurities: How ChemAIRS Supports the Synthesis of 4-Chloro-1,2,3-Triazole for Milvexian_EP15
ChemAIRS accelerated the development of Milvexian—BMS/Janssen’s breakthrough oral FXIa inhibitor—by designing scalable synthetic routes for its key triazole intermediate while predicting impurities and optimizing scale-up. Transform your anticoagulant drug development with AI-driven retrosynthesis.
Utilizing ChemAIRS to Explore Synthetic Strategies for BAY 2413555: A Bayer Therapeutic Candidate Targeting Heart Failure_EP16
ChemAIRS demonstrated its synthetic versatility by designing multiple routes to Bayer’s M₂ PAM BAY 2413555—a heart failure candidate—identifying key disconnections, optimizing intermediates, and providing scalable conditions. While preclinical vascular inflammation halted development, our AI-driven platform continues to accelerate cardiovascular drug discovery with precision.
Leveraging ChemAIRS to Investigate Synthetic Approaches for Azetidine-Based αvβ6 Integrin Inhibitors: Core Modifications of GSK3335103_EP17
ChemAIRS optimized synthetic routes for GSK’s novel αvβ6 integrin inhibitors—key targets in TGF-β1-driven fibrosis—enhancing scalability, selectivity, and yield while reducing side reactions. These orally bioavailable candidates (including leads (S)-20 and 28) show promise for treating idiopathic pulmonary fibrosis, demonstrating AI’s power in accelerating antifibrotic drug development.
Utilizing ChemAIRS to Investigate Synthesis Strategies for AZD5462: A Promising RXFP1 Agonist for Heart Failure Treatment_EP12
ChemAIRS accelerated the development of AstraZeneca/Mitsubishi Tanabe’s RXFP1 modulator AZD5462—a relaxin H2 mimetic for heart failure—by predicting synthetic routes, flagging side reactions, and proposing scalable alternatives. Transform your cardiovascular drug discovery with AI-driven retrosynthesis
Enhancing the Retrosynthetic Strategy for Orforglipron (LY3502970) Using ChemAIRS: Developing a More Streamlined and Efficient Synthetic Route Suggestion_EP18
ChemAIRS revolutionized the synthesis of Eli Lilly’s oral GLP-1 agonist Orforglipron—optimizing key intermediates and streamlining scale-up conditions for commercial-ready production. Accelerate your metabolic drug development with AI-driven retrosynthesis.
Leveraging ChemAIRS to Investigate Synthetic Strategies for Tetrahydrobenzoazepine Core of BTK Inhibitor BIIB091_EP13
ChemAIRS, an AI-powered retrosynthesis tool, was employed to explore the synthesis and process development of the tetrahydrobenzoazepine core in BTK inhibitor BIIB091. The software proposed an alternative reductive amination strategy for the final step, diverging from Biogen’s reported biocatalytic transamination approach. Additionally, ChemAIRS optimized conditions for the key ring-forming step and identified potential side reactions that could impact cyclization efficiency, offering valuable insights for reaction optimization.